224 related articles for article (PubMed ID: 34414123)
1. Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.
Finkelmeier F; Scheiner B; Leyh C; Best J; Fründt TW; Czauderna C; Beutel A; Bettinger D; Weiß J; Meischl T; Kütting F; Waldschmidt DT; Radu P; Schultheiß M; Peiffer KH; Ettrich TJ; Weinmann A; Wege H; Venerito M; Dufour JF; Lange CM; Pinter M; Waidmann O
Liver Cancer; 2021 Jul; 10(4):360-369. PubMed ID: 34414123
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial.
El-Khoueiry AB; Meyer T; Cheng AL; Rimassa L; Sen S; Milwee S; Kelley RK; Abou-Alfa GK
BMC Cancer; 2022 Apr; 22(1):377. PubMed ID: 35397508
[TBL] [Abstract][Full Text] [Related]
4. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
Kelley RK; Ryoo BY; Merle P; Park JW; Bolondi L; Chan SL; Lim HY; Baron AD; Parnis F; Knox J; Cattan S; Yau T; Lougheed JC; Milwee S; El-Khoueiry AB; Cheng AL; Meyer T; Abou-Alfa GK
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847838
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.
Kanzaki H; Ogasawara S; Okubo T; Itokawa N; Yoshino R; Fujimoto K; Kogure T; Yumita S; Ishino T; Ogawa K; Iwanaga T; Nakagawa M; Fujiwara K; Kojima R; Koroki K; Inoue M; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Itobayashi E; Atsukawa M; Kato J; Kato N
Drugs Real World Outcomes; 2023 Dec; 10(4):513-520. PubMed ID: 37466822
[TBL] [Abstract][Full Text] [Related]
6. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis.
Bang YH; Lee CK; Yoo C; Chon HJ; Hong M; Kang B; Kim HD; Park SR; Choi WM; Choi J; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Ryu MH; Ryoo BY
Ther Adv Med Oncol; 2022; 14():17588359221097934. PubMed ID: 35602405
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley RK; Rimassa L; Cheng AL; Kaseb A; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Banerjee K; Hazra S; Fawcett J; Yau T
Lancet Oncol; 2022 Aug; 23(8):995-1008. PubMed ID: 35798016
[TBL] [Abstract][Full Text] [Related]
8. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
Chan SL; Ryoo BY; Mo F; Chan LL; Cheon J; Li L; Wong KH; Yim N; Kim H; Yoo C
J Hepatol; 2024 Apr; ():. PubMed ID: 38570034
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
10. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma.
Tovoli F; Dadduzio V; De Lorenzo S; Rimassa L; Masi G; Iavarone M; Marra F; Garajova I; Brizzi MP; Daniele B; Trevisani F; Messina C; Di Clemente F; Pini S; Cabibbo G; Granito A; Rizzato MD; Zagonel V; Brandi G; Pressiani T; Federico P; Vivaldi C; Bergna I; Campani C; Piscaglia F
Liver Cancer; 2021 Jul; 10(4):370-379. PubMed ID: 34414124
[TBL] [Abstract][Full Text] [Related]
11. The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges.
D'Alessio A; Prete MG; Cammarota A; Personeni N; Rimassa L
J Hepatocell Carcinoma; 2021; 8():177-191. PubMed ID: 33824862
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T; Kaseb A; Cheng AL; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Milwee S; Wang Z; Curran D; Kelley RK; Rimassa L
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):310-322. PubMed ID: 38364832
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
[TBL] [Abstract][Full Text] [Related]
14. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching.
Adhoute X; De Matharel M; Mineur L; Pénaranda G; Ouizeman D; Toullec C; Tran A; Castellani P; Rollet A; Oules V; Perrier H; Si Ahmed SN; Bourliere M; Anty R
World J Gastrointest Oncol; 2022 Aug; 14(8):1510-1527. PubMed ID: 36160737
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
Kudo M; Tsuchiya K; Kato N; Hagihara A; Numata K; Aikata H; Inaba Y; Kondo S; Motomura K; Furuse J; Ikeda M; Morimoto M; Achira M; Kuroda S; Kimura A
J Gastroenterol; 2021 Feb; 56(2):181-190. PubMed ID: 33392749
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.
Yoo C; Kim JH; Ryu MH; Park SR; Lee D; Kim KM; Shim JH; Lim YS; Lee HC; Lee J; Tai D; Chan SL; Ryoo BY
Liver Cancer; 2021 Apr; 10(2):107-114. PubMed ID: 33977087
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers.
Himmelsbach V; Pinter M; Scheiner B; Venerito M; Sinner F; Zimpel C; Marquardt JU; Trojan J; Waidmann O; Finkelmeier F
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406493
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
